CytomX Therapeutics, Inc. (CTMX)

NASDAQ: CTMX · IEX Real-Time Price · USD
2.250
+0.600 (36.36%)
At close: Feb 27, 2024, 4:00 PM
2.240
-0.010 (-0.44%)
After-hours: Feb 27, 2024, 7:52 PM EST
36.36%
Market Cap 148.05M
Revenue (ttm) 75.55M
Net Income (ttm) -29.36M
Shares Out 66.99M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,623,243
Open 1.660
Previous Close 1.650
Day's Range 1.660 - 2.440
52-Week Range 1.040 - 2.440
Beta 0.84
Analysts Hold
Price Target 2.73 (+21.33%)
Earnings Date Mar 25, 2024

About CTMX

CytomX Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company's pipeline comprises therapeutic candidates across multiple treatment modalities, including antibody-drug conjugates (ADCs), T-cell engaging bispecific antibodies, and immune modulators, such as cytokines and checkpoint inhibitors. CX-2029 is an investigational conditional ADC directed toward CD71. Its clinical pipeline also includes cancer imm... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2015
Employees 116
Stock Exchange NASDAQ
Ticker Symbol CTMX
Full Company Profile

Financial Performance

In 2022, CTMX's revenue was $53.16 million, an increase of 42.48% compared to the previous year's $37.31 million. Losses were -$99.32 million, -14.29% less than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CTMX stock is "Hold." The 12-month stock price forecast is $2.73, which is an increase of 21.33% from the latest price.

Price Target
$2.73
(21.33% upside)
Analyst Consensus: Hold
Stock Forecasts

News

CytomX Therapeutics to Present at Upcoming March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that man...

13 hours ago - GlobeNewsWire

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 -

4 weeks ago - GlobeNewsWire

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sea...

6 weeks ago - GlobeNewsWire

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data anticipated in  the 2 nd half of 2024 -

7 weeks ago - GlobeNewsWire

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sea...

2 months ago - GlobeNewsWire

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 -

4 months ago - GlobeNewsWire

CytomX Therapeutics to Present at Upcoming November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that man...

4 months ago - GlobeNewsWire

CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it ...

4 months ago - GlobeNewsWire

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

- IND filing for CX-801 anticipated by the end of 2023 - SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally...

4 months ago - GlobeNewsWire

CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

- CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor payload -

4 months ago - GlobeNewsWire

CytomX Therapeutics to Present at Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that ma...

6 months ago - GlobeNewsWire

CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sea...

7 months ago - GlobeNewsWire

CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

- CX-904 (EGFRxCD3) initial Phase 1 dose escalation data anticipated first half of 2024 -                         - IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) antici...

7 months ago - GlobeNewsWire

CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it ...

7 months ago - GlobeNewsWire

CytomX Therapeutics Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that on...

7 months ago - GlobeNewsWire

CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appo...

8 months ago - GlobeNewsWire

CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.

- Financing is expected to extend cash runway into the 2 nd half of 2025 based on current operating plans, enabling the Company to reach multiple clinical milestones -

8 months ago - GlobeNewsWire

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sea...

9 months ago - GlobeNewsWire

CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

- Continued progress in Phase 1 dose escalation for CX-904 (EGFRxCD3) -                         - IND enabling activities on track for filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon a...

10 months ago - GlobeNewsWire

CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023

SOUTH SAN FRANCISCO, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it w...

10 months ago - GlobeNewsWire

CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Se...

11 months ago - GlobeNewsWire

CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

- Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) i...

1 year ago - GlobeNewsWire

CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023

SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it...

1 year ago - GlobeNewsWire

CytomX Therapeutics to Present at Upcoming March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sea...

1 year ago - GlobeNewsWire

CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

-Achievement of clinical candidate is the first in the multi-target collaboration and triggers a $5 million milestone payment to CytomX-

1 year ago - GlobeNewsWire